THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION No. 810 Session of 2020

INTRODUCED BY BROWN, HENNESSEY, KORTZ, KIM, BIZZARRO, SONNEY, PICKETT, MILLARD, READSHAW, FREEMAN, BURNS, MURT, LONGIETTI, SCHMITT, SCHLEGEL CULVER, RYAN, NEILSON, ROZZI, GAINEY AND YOUNGBLOOD, MARCH 13, 2020

REFERRED TO COMMITTEE ON HEALTH, MARCH 13, 2020

A RESOLUTION

1 2	Recognizing the month of September 2020 as "Polycystic Kidney Disease Awareness Month" in Pennsylvania.
3	WHEREAS, Polycystic kidney disease (PKD) is a genetic disease
4	that is passed from an affected parent to child and causes
5	uncontrolled growth of cysts in the kidney; and
6	WHEREAS, PKD affects all racial and ethnic groups equally and
7	occurs equally in men and women; and
8	WHEREAS, Approximately 600,000 people in the United States
9	have PKD and it is the fourth leading cause of kidney failure;
10	and
11	WHEREAS, There are three types of PKD: autosomal dominant
12	(ADPKD), autosomal recessive (ARPKD) and acquired cystic (ACKD);
13	and
14	WHEREAS, ADPKD is the most common form of PKD, comprising
15	90% of all PKD cases, and it is passed from parent to child
16	genetically by dominant inheritance; and
17	WHEREAS, Symptoms of ADPKD typically begin between 30 and 40

years of age, but can begin as early as childhood; and 1 2 WHEREAS, ARPKD is passed from parent to child genetically by 3 recessive inheritance; and WHEREAS, ARPKD is a rare form of PKD and occurs in 1 in 4 5 20,000 children worldwide; and 6 WHEREAS, Symptoms of ARPKD begin in the earliest months of 7 life, even in the womb; and 8 WHEREAS, ARPKD is very serious because it progresses rapidly and is often fatal in the first few months of life; and 9 10 WHEREAS, ACKD is most often associated with kidney failure and dialysis because it can cause long-term damage and severe 11 scarring in the kidney; and 12 13 WHEREAS, ACKD develops in approximately 90% of people who have been on dialysis for at least five years; and 14 15 WHEREAS, Symptoms that may indicate that an individual has PKD include back or side pain, an increase in the size of the 16 abdomen, blood in the urine, frequent bladder or kidney 17 18 infections, fluttering or pounding in the chest and high blood 19 pressure; and 20 WHEREAS, High blood pressure is the most common sign of PKD; 21 and WHEREAS, If high blood pressure is treated, the treatment can 22 23 help slow or even prevent kidney failure; and 24 WHEREAS, Approximately 50% of individuals with PKD have 25 kidney failure by 60 years of age, and 60% of individuals have kidney failure by 70 years of age; and 26 WHEREAS, The only options available for individuals 27 28 experiencing kidney failure are dialysis or a kidney transplant; 29 and

WHEREAS, Although PKD has no cure, supportive treatments can 30 20200HR0810PN3468

- 2 -

be administered to control symptoms, help slow cyst growth and
 prevent or slow down the loss of kidney function as a result of
 PKD; and

4 WHEREAS, Supportive treatments for PKD include all of the 5 following:

6 (1) Carefully controlling blood pressure.

7 (2) Promptly treating bladder or kidney infections with8 antibiotics.

9 (3) Drinking a lot of water when blood in the urine is 10 first noticed.

11 (4) Using medication to control pain.

12 (5) Maintaining a healthy lifestyle by quitting smoking,
13 exercising, controlling weight, avoiding caffeine and
14 reducing salt intake;

15 and

16 WHEREAS, The average annual cost of dialysis treatments is 17 \$89,000 per patient, and the total average annual cost of 18 dialysis treatments is \$42 billion nationwide; therefore be it 19 RESOLVED, That the House of Representatives recognize the 20 month of September 2020 as "Polycystic Kidney Disease Month" in 21 Pennsylvania.

- 3 -